Category: Uganda

Recording now available! Uganda Chapter Webinar: Communicating Population PK/PD Modelling Results with clarity

Download the slides here Date: Tuesday 11 August 2026 (4 pm Ugandan Time) About the speaker Aida Kawuma, PhD is a founding member of the Ugandan Chapter of Pharmacometrics Africa. She is passionate about improving the contributions of African scientists in pharmacology and pharmacometrics. She is a scientist at Pumas-AI with expertise in population PK/PD modelling and model-informed drug development across a diverse range of molecules and disease areas. She is also a member of the MILK Centre modelling group at the Infectious Diseases Institute, Makerere University. About this series Sharing knowledge, presenting advances and discussing best practices in pharmacometrics, featuring locally-relevant case studies in application of PBPK and pop-PK Who should attend: Anyone interested in learning how pharmacometrics helps to enable safe and effective use of medication Cost: Totally Free

Read More »

Uganda Chapter Webinar: Pharmacometric modelling for mechanistic understanding of biomarker data

Date: Tuesday 24 March 2026 (2 pm Ugandan Time) About the speaker Francis Williams Ojara is a Post-doctoral pharmacometric modeler at the Infectious Diseases Institute and a lecturer of pharmacology at Gulu University. He holds a Doctorate in Natural Sciences (focusing on Pharmacometrics). His research covers modelling of pharmacokinetic-(and pharmacodynamic) data in oncology and infectious diseases, with current interests in understudied populations such as the pediatrics and pregnant mothers. He has strong interest in training and mentoring scholars into pharmacometrics and establishing potent global networks to support the growth of pharmacometrics in Uganda and Africa. About this series Sharing knowledge, presenting advances and discussing best practices in pharmacometrics, featuring locally-relevant case studies in application of PBPK and pop-PK Who should attend: Anyone interested in learning how pharmacometrics helps to enable safe and effective use of medication Cost: Totally Free

Read More »

Systematic Review: Maternal-to-Infant Transfer of Medications for Type 2 Diabetes Mellitus Via Breastmilk: A Systematic Review of Available Evidence and Clinical Guidelines

Read the full paper here Abstract: This review evaluates the available pharmacokinetic data on the plasma-to-breastmilk transfer of first- and second-line T2DM drugs against available clinical guideline recommendations. A list of drug therapies for treating T2DM was generated from national and international clinical guidelines. A systematic search of research articles reporting human plasma and breastmilk drug concentrations was conducted in Scopus, PubMed, Google Scholar, and LactMed® in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Studies evaluating breastmilk drug transfer in T2DM, with fully accessible abstract and main text reported in English, were included. Study quality was evaluated using the ClinPK checklist. Authors evaluated clinical guideline recommendations on the use of T2DM drugs in lactation and the basis upon which such recommendations were made. Only 5 out of 20 drugs (metformin, glyburide, glipizide, tolbutamide, and semaglutide) have clinical data on plasma-to-breastmilk transfer. Metformin and tolbutamide were detectable in maternal plasma and breastmilk. Half (51.7%) of guideline recommendations provide explicit guidance. Only 4.4% of recommendations were based on clinical evidence. Over half (57.8%) of recommendations were accessible online, and most guideline recommendations (78%) were against the use of antiglycemic agents while breastfeeding. The scarce clinical evidence to guide T2DM drug therapy during breastfeeding available has several design and methodological limitations. Published recommendations remain largely inconsistent, thus perpetuating uncertainty in the use of T2DM drug therapies in lactation. Addressing knowledge gaps is critical in developing clinical consensus to optimize T2DM drug therapy among breastfeeding mothers.

Read More »

Review Paper: Treating Pregnant and Lactating Women: Insights from Clinical Pharmacology

Read the full paper here Abstract: Pregnant and lactating women have historically been excluded from clinical trials, limiting data on drug pharmacokinetics, safety, and efficacy in these populations. Recent legislative frameworks have catalyzed efforts to include these populations in research. Quantitative pharmacology approaches such as PBPK support optimized trial designs, safer dosing regimens, and ethical research frameworks. Emerging technologies further enhance insights drug exposures in mother-infant dyads  

Read More »

Research Paper: Model-based evaluation of the interaction between ritonavir-boosted atazanavir and rifampicin in Ugandan adults with HIV

Read the full paper here Abstract: The DERIVE study (NCT04121195) recruited Ugandan adults with HIV (not TB) on ATV/r-based second-line antiretroviral therapy, and collected intensive plasma and PBMC pharmacokinetic samples during four visits with a sequential dose-escalation design. ATV/r plasma and PBMC concentrations were analysed with population pharmacokinetic modelling in NONMEM.

Read More »

Research Paper: Population pharmacokinetics of levofloxacin in breastmilk in patients with rifampicin-resistant tuberculosis

Read the full paper here Abstract: Levofloxacin is a widely used antibiotic included in rifampicin-resistant tuberculosis (RR-TB) treatment. Data describing levofloxacin concentrations in breastmilk and infant exposure are limited. We analysed data from two South African studies of breastfeeding women receiving levofloxacin (750–1000 mg daily) for RR-TB. Plasma and breastmilk samples were collected over eight hours, ≥5 weeks postpartum. A single plasma sample was obtained from breastfed infants. Twenty women contributed paired plasma-breastmilk samples, 15 plasma concentrations from breastfed infants were available. Using nonlinear mixed-effects modelling, levofloxacin equilibrated rapidly between plasma and breastmilk (7.50 min half-life; 95% CI: 3.89–11.5), with a breastmilk: plasma ratio of 1.46 (95% CI: 1.40–1.52). The relative infant dose through breastfeeding was 6–8% of the recommended 15–20 mg/kg/day adult and paediatric dose, confirmed by low (but detectable) concentrations in some infants. It is unclear whether these low infant concentrations may be prophylactic or instead contribute to the development of drug resistance.  

Read More »

Uganda Chapter Webinar: PK and PD of Protein Therapeutics

11 November 20252:00 PM – 3:00 PM EAT (1h) About the speaker Bernd Meibohm, PhD, FCP, FAAPS is a UTHSC Distinguished Professor of Pharmaceutical Sciences and Associate Dean for Research and Graduate Programs at the College of Pharmacy, The University of Tennessee Health Science Center, Memphis, Tennessee, USA.  He also serves as Chair of the University of Tennessee Department of Pharmaceutical Sciences and holds the Harriet S. Van Fleet Endowed Professorship in Pharmaceutics. Dr. Meibohm received his pharmacy degree and doctorate in pharmaceutics from Technical University Carolo-Wilhelmina, Braunschweig, Germany. After completion of a clinical pharmacology research fellowship at the University of Florida in 1997, he joined the faculty of the University of South Carolina, and in 1999 the University of Tennessee.  Dr. Meibohm’s scientific interests include bacterial and viral infectious diseases, pediatric pharmacotherapy and the application of pharmacometric modeling and simulation techniques in preclinical and clinical drug development, with specific focus on therapeutic proteins.  His research has resulted in over 230 scientific papers and book chapters (>14,000 citations; h-index 58), three textbooks, 200 abstracts, and over 250 invited scientific presentations to national and international audiences. Dr. Meibohm is a Fellow of the American Association of Pharmaceutical Scientists (AAPS) and the American College of Clinical Pharmacology (ACCP). He was the President of ACCP 2014-2016 and served on its Board of Regents 2008-2018. He also served as 2010 Chair for the ‘Pharmacokinetics, Pharmacodynamics and Drug Metabolism’ section of AAPS, as 2016-2019 Member-at-Large on the Board of Directors of AAPS, and has recently

Read More »

Watch: Leveraging PMX for Optimal Study designs in Resource-Limited Settings

Recorded: 9 Sept 20254pm EAT / 3pm CEST (1h Leveraging PMX for Optimal Study designs in Resource-Limited Settings About the SpeakerFrancis Williams Ojara is a Post-doctoral pharmacometric modeler at the Infectious Diseases Institute and a lecturer of pharmacology at Gulu University. He holds a Doctorate in Natural Sciences (focusing on Pharmacometrics). His research covers modelling of pharmacokinetic-(and pharmacodynamic) data in oncology and infectious diseases, with current interests in understudied populations such as the pediatrics and pregnant mothers. He has strong interest in training and mentoring scholars into pharmacometrics and establishing potent global networks to support the growth of pharmacometrics in Uganda and Africa. About this seriesSharing knowledge, presenting advances and discussing best practices in pharmacometrics, featuring locally-relevant case studies in application of PBPK and pop-PK Who should attend:Anyone interested in learning how pharmacometrics helps to enable safe and effective use of medication

Read More »

Uganda Chapter Webinar: Leveraging Pharmacometrics for Optimal Study designs in Resource-Limited Settings

9 September 20254:00 PM – 5:00 PM EAT (1h) About the speaker Francis Williams Ojara is a Post-doctoral pharmacometric modeler at the Infectious Diseases Institute and a lecturer of pharmacology at Gulu University. He holds a Doctorate in Natural Sciences (focusing on Pharmacometrics). His research covers modelling of pharmacokinetic-(and pharmacodynamic) data in oncology and infectious diseases, with current interests in understudied populations such as the pediatrics and pregnant mothers. He has strong interest in training and mentoring scholars into pharmacometrics and establishing potent global networks to support the growth of pharmacometrics in Uganda and Africa. About this series Sharing knowledge, presenting advances and discussing best practices in pharmacometrics, featuring locally-relevant case studies in application of PBPK and pop-PK Who should attend: Anyone interested in learning how pharmacometrics helps to enable safe and effective use of medication Cost: Totally Free

Read More »

Research Paper: Prevalence, safety evidence, and determinants of medicine use during breastfeeding among women in Kampala, Uganda

Read the full paper here Abstract: We conducted a cross-sectional study among 294 breastfeeding women aged 18 years and older with infants aged 12 months and below, attending six healthcare clinics in Kampala between September 2023 and January 2024. Using a structured questionnaire, we collected data on medicine use and breastfeeding practices.

Read More »
PMX Africa
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.